Haemonetics Corporation has acquired Vivasure Medical Limited for €100 million to enhance its portfolio of innovative closure devices with the PerQseal® Elite system.

Information on the Target

Vivasure Medical Limited, located in Galway, Ireland, is a leader in the development of next-generation technology for percutaneous vessel closure. Their flagship product, the PerQseal® Elite system, utilizes a proprietary bioabsorbable patch to securely seal large-bore arteriotomies and venotomies from within the vessel. This innovative approach offers a sutureless and fully absorbable solution particularly useful in structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for their arterial closure system and has already received CE Mark approval in Europe for both arterial and venous applications.

The PerQseal Elite has demonstrated its efficacy through the prospective, single-arm, multi-center ELITE arterial study, which showed no major complications at a thirty-day follow-up and eliminated the need for pre-closure procedures. This results in an immediate median time to hemostasis, enhancing procedural efficiency and patient safety.

Industry Overview in Ireland

The medical technology industry in Ireland has experienced significant growth and innovation, particularly in areas such as cardiovascular devices, diagnostics, and minimally invasive surgical technologies. Ireland is home to a robust ecosystem of medical technolog